scholarly journals Non invasive assessment of liver fibrosis in chronic hemodialysis patients with viral hepatitis C

2015 ◽  
Vol 22 ◽  
Author(s):  
Mohamed Arrayhani ◽  
Tarik Sqalli ◽  
Nada Tazi ◽  
Randa El Youbi ◽  
Safae Chaouch ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Fibrosis ◽  
Viral Hepatitis ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Non Invasive ◽  
Viral Hepatitis C

P.366 Simple blood tests as non-invasive markers of liver fibrosis in hemodialysis patients with hepatitis C virus (HCV) chronic infection

2006 ◽  
Vol 36 ◽  
pp. S173
Author(s):  
L.L. Schiavon ◽  
J.L. Narciso ◽  
R.J. Carvalho Filho ◽  
J.P. Sampaio ◽  
V.P. Lanzoni ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Chronic Infection ◽  
Hemodialysis Patients ◽  
Non Invasive ◽  
Blood Tests

scholarly journals NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS USING LIVER ELASTOGRAPHY (FIBROSCAN) IN PATIENTS WITH CHRONIC INFECTION HBV AND HCV

2016 ◽  
Vol 19 (3) ◽  
pp. 55-59
Author(s):  
Andreea Rădășan ◽  
◽  
Mihai Voiculescu ◽  
Laura Elena Iliescu ◽  
◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Economic Problem ◽  
Non Invasive ◽  
Treatment And Prevention ◽  
Viral Hepatitis C ◽  
B Virus ◽  
Liver Elastography

Introduction. In recent years there have been major advances in the treatment and prevention of viral hepatitis, but this pathology is still a major health and socio-economic problem. The defining element for this disease is the liver fibrosis, a histological component of particular importance due to its role in the formation of liver lesions of cirrhosis. Thus, an essential step in the management of chronic viral hepatitis is the detection and measurement of liver fibrosis. Today we have invasive methods for detecting liver fibrosis, the liver puncture biopsy, and non-invasive methods, which in turn are divided into serum methods and imaging methods (2). Purpose of the Study. The aim of this study is to determine if transcutaneous elastography (FibroScan) is equally reliable in case of viral hepatitis B, as with viral hepatitis C. Material and Method: The study comprises a total of 1,127 patients with liver disease of HBV and HCV aetiology. These patients were examined using FibroScan in the period July 2009 - April 2011. Results: Of the 1,177 patients investigated using FibroScan, 40 underwent liver biopsy as well. Of these, 82% have obtained same stages of liver fibrosis in these two investigations, and 18% achieved different stages of fibrosis in these two tests. For the patients with HCV infection, we obtained a 67.81% match of the two non-invasive tests, FibroScan and FibroMax, and a 79.16% match of FibroScan compared to the Liver Biopsy. For the B virus, the compliance is even better, of 75% (FibroScan - FibroMax), and 80% for FibroScan - LB. Conclusions: FibroScan is one of the non-invasive assessment methods of liver fibrosis with diagnose accuracy similar to FibroMax and close to Liver Biopsy.

scholarly journals The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242601
Author(s):  
Jia-Jung Lee ◽  
Yu-Ju Wei ◽  
Ming-Yen Lin ◽  
Sheng-Wen Niu ◽  
Po-Yao Hsu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Diagnostic Accuracy ◽  
Chronic Hepatitis C ◽  
Transient Elastography ◽  
Hemodialysis Patients ◽  
Accurate Assessment ◽  
Non Invasive

Background The accurate assessment of liver fibrosis among hemodialysis patients with chronic hepatitis C (CHC) is important for both treatment and for follow up strategies. Applying the non-invasive methods in general population with viral hepatitis have been successful but the applicability of the aminotransferase/platelet ratio index (APRI) or the fibrosis-4 index (FIB-4) in hemodialysis patients need further evaluation. Materials and methods We conducted a prospective, multi-center, uremic cohort to verify the applicability of APRI and FIB-4 in identifying liver fibrosis by reference with the standard transient elastography (TE) measures. Results There were 116 CHC cases with valid TE were enrolled in our analysis. 46 cases (39.6%) were classified as F1, 35 cases (30.2%) as F2, 11 cases (9.5%) as F3, and 24 cases (20.7%) as F4, respectively. The traditional APRI and FIB-4 criteria did not correctly identify liver fibrosis. The optimal cut-off value of APRI was 0.28 and of FIB-4 was 1.91 to best excluding liver cirrhosis with AUC of 76% and 77%, respectively. The subgroup analysis showed that female CHC hemodialysis patients had better diagnostic accuracy with 74.1% by APRI. And CHC hemodialysis patients without hypertension had better diagnostic accuracy with 78.6% by FIB-4. Conclusions This study confirmed the traditional category level of APRI and FIB-4 were unable to identify liver fibrosis of CHC hemodialysis patients. With the adjusted cut-off value, APRI and FIB-4 still showed suboptimal diagnostic accuracy. Our results suggest the necessary of TE measures for liver fibrosis in the CHC uremic population.

scholarly journals Viral Hepatitis C (HCV) in Hemodialysis

2020 ◽  
Vol 1 (2) ◽  
pp. 01-05
Author(s):  
Seba Atmane
Keyword(s):  
Risk Factors ◽  
Hepatitis C ◽  
Blood Transfusion ◽  
Dual Therapy ◽  
Hemodialysis Patients ◽  
Virologic Response ◽  
Chronic Hemodialysis ◽  
Early Virologic Response ◽  
Viral Hepatitis C ◽  
Hcv Transmission

The aim of the study is to show the prevalence and risk factors of HCV at our hemodialysis (HD) center , in a study carried out on chronic hemodialysis patients during the year 2019, we identified eight cases out of 87 patients infected with HCV, or 9%. The average age in this population is 48 years, dialysed for an average of 15 years. Viral infection was discovered on average 12.5 years after the start of hemodialysis, during a routine screening examination. In this series, the genotype 1b was found in 2 cases (25%). Seven patients were treated out of the eight HCV hemodialysis patients, received dual therapy with sofosbuvir 400mg and daclar 60 mg for three months, with an early virologic response. A study done during a previous period, between 2015 and 2018, in the same center, looking at the risk factors for HCV transmission: 11 cases out of 134 hemodialysis patients infected with HCV. Among these cases, we noted the following factors; Blood transfusion: 3 cases (27.2%), surgery: 4 cases (45.4%), dental care: 2 cases (18%), no obvious cause: 2 cases (9%). Serologically ; HCV antibodies positive: 11/134, i.e. an 8.2% seroprevalence, PCR-viral RNA was positive in 10 out of 11 patients, i.e. a prevalence of 7.4% by PCR, number of copies: Above 1.03x 1, 000,000 (100%), number of Logs: Sup to 3.32 (100%), negative PCR: 01 patient.

Interest of hyaluronic acid (HA) in assessment of liver fibrosis in chronic viral hepatitis C

1995 ◽  
Vol 108 (4) ◽  
pp. A1140
Author(s):  
B. Oui ◽  
H. Trouette ◽  
B. Le Bail ◽  
G. Lacape ◽  
M. Fonck ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

scholarly journals Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis

1996 ◽  
Vol 42 (4) ◽  
pp. 558-563 ◽  
Author(s):  
J Guéchot ◽  
A Laudat ◽  
A Loria ◽  
L Serfaty ◽  
R Poupon ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Fibrosis ◽  
Diagnostic Accuracy ◽  
Viral Hepatitis ◽  
Roc Curves ◽  
Chronic Viral Hepatitis ◽  
Type Iii ◽  
Amino Terminal ◽  
Viral Hepatitis C ◽  
Chronic Viral Hepatitis C

Abstract Diagnostic accuracy of two serum markers of liver fibrosis, hyaluronan (HA) and amino-terminal peptide of type III procollagen (P-III-P), was studied in a cohort of 326 untreated patients with chronic viral hepatitis C. Both P-III-P (RIA-gnost P-III-P, Behring Diagnostic) and HA (HA-test, Pharmacia) serum concentrations correlated with the histological grades of liver fibrosis (P < 0.001). Receiver-operating characteristic (ROC) curves showed that serum HA had greater diagnostic performance than P-III-P, both for discriminating patients with extensive liver fibrosis from those with no or mild fibrosis (area under the ROC curves: 0.864 vs 0.691, P <0.001) or for discriminating patients with cirrhosis from those without cirrhosis (area under the ROC curves: 0.924 vs 0.734, P <0.001). At cutoff values of 0.8 kU/L for serum P-III-P and 85 micrograms/L for serum HA, sensitivities were 70.0% and 64.5%, and specificities were 63.4% and 91.2%, respectively, for discriminating patients with extensive liver fibrosis from those with no or mild fibrosis. At the cutoff values of 1.0 kU/L for serum P-III-P and 110 micrograms/L for serum HA, sensitivities were 60.0% and 79.2%, and specificities were 74.0% and 89.4%, respectively, for discriminating patients with liver cirrhosis from those without cirrhosis. We conclude that, because the diagnostic accuracy of serum HA is greater than that of serum P-III-P as a marker of liver fibrosis, serum HA should be preferred when monitoring liver fibrosis in patients with chronic viral hepatitis C.

Sign in / Sign up

Export Citation Format

Share Document